BioVie Inc. (BIVI)
BIVI Stock Price Chart
Explore BioVie Inc. interactive price chart. Choose custom timeframes to analyze BIVI price movements and trends.
BIVI Company Profile
Discover essential business fundamentals and corporate details for BioVie Inc. (BIVI) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
18 Sept 2020
Employees
14.00
Website
https://bioviepharma.comCEO
Cuong Viet Do
Description
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.
BIVI Financial Timeline
Browse a chronological timeline of BioVie Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 9 Feb 2026
Upcoming earnings on 12 Nov 2025
EPS estimate is -$3.60.
Earnings released on 15 Aug 2025
EPS came in at -$0.24 surpassing the estimated -$4.40 by +94.63%.
Stock split effective on 7 Jul 2025
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 12 May 2025
EPS came in at -$1.50 surpassing the estimated -$3.20 by +53.13%.
Earnings released on 11 Feb 2025
EPS came in at -$4.60 surpassing the estimated -$16.00 by +71.25%.
Earnings released on 13 Nov 2024
EPS came in at -$7.00 surpassing the estimated -$16.00 by +56.25%.
Earnings released on 30 Sept 2024
EPS came in at -$66.00 falling short of the estimated -$15.00 by -340.00%.
Stock split effective on 6 Aug 2024
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 May 2024
EPS came in at -$20.00 falling short of the estimated -$0.33 by -5.96K%.
Earnings released on 12 Feb 2024
EPS came in at -$22.00 surpassing the estimated -$32.00 by +31.25%.
Earnings released on 8 Nov 2023
EPS came in at -$29.00 falling short of the estimated -$0.31 by -9.25K%.
Earnings released on 16 Aug 2023
EPS came in at -$23.00 surpassing the estimated -$37.00 by +37.84%.
Earnings released on 12 May 2023
EPS came in at -$43.00 falling short of the estimated -$0.35 by -12.19K%.
Earnings released on 10 Feb 2023
EPS came in at -$50.00 falling short of the estimated -$0.25 by -19.90K%.
Earnings released on 4 Nov 2022
EPS came in at -$38.00 falling short of the estimated -$0.28 by -13.47K%.
Earnings released on 27 Sept 2022
EPS came in at -$33.00 falling short of the estimated -$0.37 by -8.82K%.
Earnings released on 11 May 2022
EPS came in at -$0.28 surpassing the estimated -$0.42 by +33.33%.
Earnings released on 8 Feb 2022
EPS came in at -$0.28 surpassing the estimated -$0.31 by +9.68%.
Earnings released on 10 Nov 2021
EPS came in at -$23.36 .
Earnings released on 30 Aug 2021
EPS came in at -$10.18 falling short of the estimated -$2.32 by -338.79%.
Earnings released on 10 May 2021
EPS came in at -$21.50 .
Earnings released on 29 Jan 2021
EPS came in at -$21.97 .
Earnings released on 5 Nov 2020
EPS came in at $122.81 .
BIVI Stock Performance
Access detailed BIVI performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.